Released on June 16, 2022
Evusheld™ Now Available
Evusheld™ is available in Saskatchewan for pre-exposure prophylaxis of COVID-19 in adults and adolescents (12 years of age or older), weighing at least 40 kg, who have not had a known recent exposure to an individual affected with COVID-19 and:
- Who are immunocompromised and are unlikely to mount an adequate immune response to vaccination; or
- For whom COVID-19 vaccination is not recommended.
If Evusheld™ is being considered for use, it should be on a case-by-case basis where the potential benefit is expected to outweigh any potential risk. There is very strict criteria for eligibility, and Evusheld™ is not suitable for everyone. Consult your prescriber (physician or nurse practitioner) to discuss whether this is an option for you. Evusheld™ is only available if a prescription is issued by your prescriber.
Full eligibility details are available at Saskatchewan.ca/covid19-treatments.
Weekly COVID-19 Epi Report
Issued Thursdays, the Ministry of Health's COVID-19 integrated epidemiology (epi) report utilizes multiple data sources and includes laboratory-confirmed cases, deaths, tests, vaccination information provincially and by zones, as well as hospital and ICU census trends and distribution of rapid antigen tests. The epi report this week looks at data from Sunday, June 5, to Saturday, June 11, 2022. The hospitalization data is a comparison from June 9-15, 2022.
The integrated epi report can be found online at saskatchewan.ca/COVID-19-cases.
Summary for the week of June 5 - 11, 2022
- 5,880 laboratory tests were performed in Saskatchewan reflecting 4.9 tests performed per 1,000 population. The number of tests was nearly identical to the number of tests in the previous week (5,888).
- The weekly test positivity of 6.5 per cent, is an increase from the previous week (4.6 per cent).
- 394 new cases were confirmed reflecting 24 laboratory-confirmed cases per 100,000 population, higher than the number of new cases in the previous week (285).
- The majority of laboratory-confirmed cases this week were 50 years and older (54.8 per cent).
- There were 94 new lineage results reported this week. Of the 94 variants of concern identified by whole genome sequencing, 100 per cent were Omicron.
- The Omicron BA.2 sublineage accounted for 90.4 per cent of the variants of concern reported this week. BA.2 sublineage is more transmissible compared to pre-variant 2020 COVID-19 and BA.1 sub-lineages but there is no current evidence of increased severity.
There were 17 newly-reported COVID-19 deaths (Two within the week, and 15 occurred earlier (September 28, 2021 to June 4, 2022) but were reported this week, higher compared to the previous week (10). A regular audit process, which has been used throughout the pandemic, discovered the missing information and these were included in this week’s case count.
- There were 20.5 COVID-like illness patients per 1,000 emergency department visits which was a decrease from last week (22 per 1,000).
- Five (5) confirmed COVID-19 outbreaks in long-term care and care home settings were reported this week.
- As of June 4, 2022, of the population five years and older, 86 per cent received at least one dose of a two dose COVID-19 vaccine and 81.1 per cent completed a series.
- Among the population 18 years and older, 52.6 per cent had received at least one booster vaccination.
- As of June 12, 2022, there have been 543 Paxlovid prescriptions, and there have been 41 Remdesivir prescriptions with a total of 118 infusions completed.
- More than 21.3 million rapid antigen test kits have been distributed in the province. They are easily accessible at more than 600 locations.
For more information, contact: